Cape Fear BioCapital
Venture capitalDurham · Pre-Seed–Series B · 3 people tracked
Investment thesis
Cape Fear BioCapital partners with founders at the earliest stages, before most institutional capital is available, providing operational experience, hands-on company building, and a resource network to turn science into medicine. The firm writes first checks and joins syndicates in therapeutics companies rooted in North Carolina, leveraging technology and talent from Duke, UNC, NC State, and the broader NC life sciences corridor. It seeks genuinely differentiated biology — validated mechanisms, novel modalities, and category-creating platforms — backing both multi-indication platform companies and single-asset programs. The firm targets companies within roughly three years of an IND filing where its capital can meaningfully accelerate the path to the clinic.
Source: firm website, verified Aug 7, 2026.
Team · 3 people
from the firm's websiteWhat they invest in
from 5 of 6 portfolio companiesBiotech ×5Healthtech ×3AI & Machine Learning ×1Deep Tech ×1Hardware ×1Medical Devices ×1
HQs:United States×5
Investments · 6 tracked
founders shown can be your intro pathEldec is a biotechnology company developing peptide-based therapeutics targeting SPLUNC1's modulation of Orai1 activity, with lead programs ELD615 and ELD607 for lung diseases such as cystic fibrosis and non-CF bronchiectasis.
BiotechHealthtechChapel Hill, US
Robert Tarran(Co-founder, President & Chief Scientific Officer)Robert Schotzinger(Executive Officer, Director)Saira Ahmad(Co-founder)Flori Sassano(Co-founder)Robert J. Schotzinger(Chairman & Chief Executive Officer)Robert Hughes(Chief Financial Officer)
Early-stage oncology company developing a breakthrough siRNA platform to target undruggable cancer pathways.
BiotechPittsboro, US
Joe McMahon(Director)Chad V. Pecot(Executive Officer, Director)Michael Dombeck(Executive Officer, Director)Sue Mahony(Director)
Incyclix Bio is a clinical-stage biotech company developing cell cycle control therapies that target the aberrant cell proliferation driving cancers, with a lead CDK2 inhibitor (INX-315).
BiotechHealthtechDurham, US
Norman Sharpless(Member of the Board of Managers.)Fredric N. Eshelman(Executive Officer and member of the Board of Managers.)Patrick Roberts(Executive Officer and member of the Board of Managers.)Sid Subramony(Member of the Board of Managers.)
Ten63 develops drug-discovery technology that combines generative chemistry with quantum-accurate molecular simulation, including BEYOND (a large quantum chemistry model) and Sentinel (a virtual CSO for target selection), to design therapeutics against previously undruggable targets.
AI & Machine LearningBiotechDeep TechDurham, US
Marcel Frenkel(Executive Officer, Director)Mark A. Hallen(Executive Officer, Director)Damien Petty(Director)Jia Wei Xu(Director)
Thoracic Innovations is a medical device company that develops products using computer-aided design, rapid prototyping, and 3D printing, with a focus on the cardiothoracic and thoracic clinical area.
BiotechHardwareHealthtechMedical DevicesChapel Hill, US
Founder of Thoracic Innovations(Founder)
Frequently asked questions
- What stage does Cape Fear BioCapital invest at?
- Cape Fear BioCapital invests at the Pre-Seed, Seed, Series A, Series B stages.
- What sectors does Cape Fear BioCapital focus on?
- Cape Fear BioCapital focuses on AI & Machine Learning, Biotech, Digital Health, Healthtech, Medical Devices.
- Where is Cape Fear BioCapital located?
- Cape Fear BioCapital is headquartered in Durham, US.
- Does Cape Fear BioCapital lead rounds?
- Yes, Cape Fear BioCapital leads investment rounds.
Similar investors
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests from seed to growth stages across artificial intelligence, health, and sustainability-focused technologies.
B Capital Group is a global venture capital firm that backs founders from early to late stage, with dedicated stage-based funds and a portfolio spanning technology, healthcare, and energy and resilience sectors.
Breyer Capital is a venture capital firm that backs high-impact entrepreneurs, making strategic investments guided by founder passion and its network of experienced investors.
DCVC (Data Collective) is a venture capital firm that backs founders building companies which apply technology to major challenges across areas such as energy, biotech, agriculture, and machine learning.
Foresite Capital is a multi-stage investment firm focused on healthcare and life sciences, backing companies across all stages of growth. It applies a data science-driven approach to invest in businesses leveraging biology and big data to transform healthcare.